Editorial: hepatocellular carcinoma risk in the era of direct-acting anti-virals-is the case closed?

P S Tan¹, S G Lim^{1

2}

Affiliations

¹ Division of Gastroenterology & Hepatology, Department of Medicine, National University Health System, Singapore.
² Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

Editorial

P S Tan et al. Aliment Pharmacol Ther. 2018 Jan.

. 2018 Jan;47(2):308-309.

doi: 10.1111/apt.14437.

P S Tan¹, S G Lim^{1

2}

¹ Division of Gastroenterology & Hepatology, Department of Medicine, National University Health System, Singapore.
² Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

No abstract available

Comment on

Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.
Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, Koyanagi T, Kato M, Shimoda S, Kajiwara E, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Aliment Pharmacol Ther. 2018 Jan;47(1):104-113. doi: 10.1111/apt.14380. Epub 2017 Oct 16. Aliment Pharmacol Ther. 2018. PMID: 29035002